ARDM. I read the Adcom transcript. Looks like the question answered to the members was a problem as most say if question was frequency of exacerbation in stead of time to first exacerbation, the majority would have voted yes. I don't know if FDA would take this comments up for the decision which is on 24th of January.
Market Data 
Markets 
AI
